Danske Bank A/S
Change company Symbol lookup
Select an option...
DNKEY Danske Bank A/S
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
CBOE Cboe Global Markets Inc
PFE Pfizer Inc

Financials : Banks | Mid Cap Value
Based in Denmark
Company profile

Danske Bank A/S is engaged in providing payment services, trading in securities and other instruments, depositing of surplus liquidity and provision of short- and long-term financing. Its segments include Personal Banking, Business Banking, Corporates & Institutions, Wealth Management, Northern Ireland, Non-core and Other Activities. The Personal Banking segment provides personal advice that addresses its customers' individual needs. The Business Banking segment offers solutions within financing, investing, cash management and risk management. The Corporates & Institutions segment provides strategic advice, financial solutions and products. The Wealth Management segment offers a range of products and services within pension savings and wealth and asset management. The Northern Ireland segment serves personal and business customers. The Non-core segment consists of loans to customers in Ireland. The Bank's Other Activities include its treasury and support functions.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
0.0901 (1.20%)
B/A Size
Day's High
Day's Low

Today's volume of 1,706 shares is on pace to be much lighter than DNKEY's 10-day average volume of 15,080 shares.


Government trial to test hydroxychloroquine, antibiotic combo in COVID-19 patients

2:37 pm ET May 14, 2020 (MarketWatch)

The National Institute of Allergy and Infectious Diseases (NIAID) said it launched a clinical trial testing hydroxychloroquine and azithromycin in 2,000 patients with mild and moderate cases of COVID-19. Hydroxychloroquine is approved by the Food and Drug Administration (FDA) to treat malaria, lupus, and rheumatoid arthritis; azithromycin is a commonly prescribed antibiotic. The trial was announced during Dr. Rick Bright's testimony (http://www.marketwatch.com/story/vaccine-expert-bright-warns-coronavirus-window-of-opportunity-closing-as-trump-calls-for-ousting-him-from-government-2020-05-14) before a House of Representatives committee on Thursday. Bright has filed a whistleblower lawsuit alleging that his reluctance to promote hydroxychloroquine as a treatment for COVID-19 led to his demotion within the National Institutes of Health. Teva Pharmaceutical Industries Ltd. (TEVA.TV) donated the hydroxychloroquine for the trial, which is evaluating whether the drug combination can prevent hospitalization and death. "Although there is anecdotal evidence that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes," NIAID director Dr. Anthony Fauci said in a statement. The FDA in March granted an emergency use authorization to hydroxychloroquine and chloroquine as COVID-19 treatments. More recently, the regulator authorized Gilead Sciences Inc.'s (GILD) remdesivir as a COVID-19 treatment; however, there are no proven, FDA-approved therapies that treat the disease caused by the novel coronavirus. There are dozens of other clinical trials (http://www.marketwatch.com/story/with-gowns-and-masks-in-short-supply-researchers-test-drugs-to-prevent-covid-19-infections-in-health-care-workers-2020-04-03) underway evaluating hydroxychloroquine in COVID-19 patients.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

May 14, 2020 14:37 ET (18:37 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.